These data demonstrate that the IDH1/2 mutations result in production of the onco-metabolite 2HG, and excess 2HG that accumulates in vivo contributes to elevated risk of malignant tumors in patients due to the inhibition of α-KG dependent dioxygenases (Fig. 1). Here, IDH1 is linked to cancer.